Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01685372 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults
A Phase 2 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01685372 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 16 participants.
The verdict
NCT01685372, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Fluzone High Dose increases the immune response to the influenza antigens contained in the vaccine compared to standard-dose Fluzone in immunocompromised children and young adults. Safety and efficacy data will also be collected.
Interventions
- BIOLOGICAL Fluzone
- BIOLOGICAL Fluzone High Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-09 |
| Est. Completion | 2017-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01685372
The ClinicalTrials.gov registry entry for NCT01685372 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluzone is the first listed.
NCT01685372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01685372 about?
NCT01685372 is a clinical study titled "Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults". The purpose of this study is to determine whether Fluzone High Dose increases the immune response to the influenza antigens contained in the vaccine compared to standard-dose Fluzone in immunocompromised children and young adults. Safety and efficacy data will also be collected.
What is the current status of trial NCT01685372?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2012-09. Estimated completion is 2017-09.
What interventions are being tested in trial NCT01685372?
The interventions under investigation include: Fluzone (BIOLOGICAL), Fluzone High Dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT01685372?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.